Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Guangyuan Lou"'
Autor:
Xiaodong Gu, Zhiyong Shi, Lan Shao, Yuxin Zhang, Yiping Zhang, Zhengbo Song, Wenxian Wang, Guangyuan Lou
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients without driver gene mutations are usually treated with immune checkpoint inhibitors (ICIs) plus pemetrexed as maintenance therapy after first-line ICIs plus 4–
Externí odkaz:
https://doaj.org/article/0e27735ed3c249f09d030e5eb4678ed4
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Anlotinib is a multitarget tyrosine kinase inhibitor for treating patients with advanced non-small cell lung cancer (NSCLC). We aimed to assess the efficacy and safety of anlotinib in elder patients with advanced NSCLC. Methods El
Externí odkaz:
https://doaj.org/article/58908db157074b2d94ee7fb8ad6d92ff
Autor:
Zhengbo Song, Guangyuan Lou, Yina Wang, Zhiping Yang, Wenxian Wang, Yongling Ji, Shiqing Chen, Chunwei Xu, Xiao Hu, Yiping Zhang
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-8 (2022)
Abstract Background Thymic epithelial tumors (TETs) are rare malignancies and the treatment options are limited. We aimed to evaluate the efficacy and safety of apatinib, an angiogenesis inhibitor, in advanced TETs. Methods This was an open-label, si
Externí odkaz:
https://doaj.org/article/3c990e5d83b842d09b7c1d703220beab
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background It has been reported that Osaka prognostic score (OPS), based on C-reactive protein (CRP), total lymphocyte counts (TLC) and albumin (ALB), was relevant to prognosis in colorectal cancer. However, the role of OPS regarding prognos
Externí odkaz:
https://doaj.org/article/d7c4766c568d46868f51f1a1fc83ce69
Autor:
Yuequan Shi, Jian Fang, Chengzhi Zhou, Anwen Liu, Yan Wang, Qingwei Meng, Cuimin Ding, Bin Ai, Yangchun Gu, Yu Yao, Hong Sun, Hui Guo, Cuiying Zhang, Xia Song, Junling Li, Bei Xu, Zhiqiang Han, Meijun Song, Tingyu Tang, Peifeng Chen, Hongmin Lu, Yongjie Shui, Guangyuan Lou, Dongming Zhang, Jia Liu, Xiaoyan Liu, Xiangning Liu, Xiaoxing Gao, Qing Zhou, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 3, Pp 412-422 (2022)
Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly understood, especially in a real‐world setting. Methods A multicenter observation
Externí odkaz:
https://doaj.org/article/c5bf6538bfd04a4cb230f7fdea6625ff
Autor:
Wenxian Wang, Zhangzhou Huang, Zongyang Yu, Wu Zhuang, Weijun Zheng, Zhijian Cai, Lei Shi, Xinmin Yu, Guangyuan Lou, Wei Hong, Yiping Zhang, Ming Chen, Zhengbo Song
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
BackgroundLung immune prognostic index (LIPI) status was recently developed to predict responses to immune checkpoint inhibitor (ICI) treatments. However, it is unclear whether LIPI is a prognostic index for both patients treated with ICI monotherapy
Externí odkaz:
https://doaj.org/article/44e558866ccc45d9a1df8bd103bfa086
Autor:
Lan SHAO, Wei HONG, Lei ZHENG, Chunxiao HE, Beibei ZHANG, Fajun XIE, Zhengbo SONG, Guangyuan LOU, Yiping ZHANG
Publikováno v:
Chinese Journal of Lung Cancer, Vol 17, Iss 5, Pp 391-400 (2014)
Background and objective Molecular targeting therapy is the direction of individualized treatment of lung cancer, scholars has been established targeted therapy prediction models which provide more guidance for clinical individual therapy. This study
Externí odkaz:
https://doaj.org/article/047b5952f4804e219a857ea6c4290bca
Analysis of the Efficacy and Survival of Third-line Treatment in Advanced Non-small Cell Lung Cancer
Autor:
Lan SHAO, Zhengbo SONG, Lin HU, Fajun XIE, Guangyuan LOU, Wei HONG, Cuiping GU, Dan HONG, Baochai LIN, Yiping ZHANG
Publikováno v:
Chinese Journal of Lung Cancer, Vol 15, Iss 6, Pp 369-374 (2012)
Background and objective The appearance of highly effective and low toxic drugs enables an increasing number of advanced non-small cell lung cancer (NSCLC) patients to receive third-line therapy. No other standard choice for third-line therapy aside
Externí odkaz:
https://doaj.org/article/4661a94520ec4f0aa478220b9d99d61d
Autor:
Lan, Shao, Guangyuan, Lou
Publikováno v:
Journal of Thoracic Disease. 14:3565-3574
Immune checkpoint inhibitors and immunotherapy have been shown to improve survival rates, especially in non-small cell lung cancer (NSCLC) patients. More recently, several trials have evaluated the clinical roles of immunotherapy as neoadjuvant setti
Publikováno v:
Contrast Media & Molecular Imaging. 2022:1-7
Even though cytopenia caused by either chemotherapy or radiotherapy is a common complication in cancer patients, chemoradiotherapy remains an essential treatment for the majority of patients. The purpose of this study was to look into the clinical ef